Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will disagree when something is posted that is clearly lacking facts about the coronavirus replication mechanism and the mechanism of 3CL Protease inhibition that Todos is using in their Tollovir antiviral.
Stating "all bets are off" is definitely a possibility where vaccines and other antirival approaches are concerned, but it seems you were suggesting that Tollovir would be included in this group, and that's clearly not the case if one has even a basic understanding of the means of coronavirus replication and how Tollovir works. If that wasn't your intent, you can reply and clear that up.
I would have posted a similar response to any other poster who made the same claim.
Have to disagree with you about all bets being off. The new Nu variant is causing great concern around the world due to the large number of mutations identified in the new strain. At this point no one knows what the impact will be, but you can be sure it will NOT impact Tollovir's ability to stop it.
The 3CL Protease is the mechanism by which ALL coronaviruses replicate. Covid-19 is a coronavirus and any mutated variant will be a coronavirus. The 3CL Protease inhibitor in Tollovir will continue stop replication in any variant of the coronavirus now or in the future. Todos Medical has chosen the best and most effective method of stopping this virus, and that's about to be known to the world.
Unless you're suggesting that somehow the virus will mutate into something other than a coronavirus.
Regarding the SEC rules and regulations, lots of investors misunderstand what is considered a "material event" as defined by the SEC. I seem to remember this topic being discussed on the AMBS board from the many hours I spent reading through years of posts, but not going to spend time trying to dig that up. Perhaps someone can ask GC on Twitter about it. Not really a concern to me.
Night Stalker, one additional request. Along with vcf5502's request for an explanation of what you're trying to convey with the charts, could you also post an image of the chart instead of the link? This would have both the chart and your explanation on the same page. There's so much data on the chart links you provide it's hard to know what data you're talking about.
CEO on Twitter - 11/25/21
Article referenced: https://metro.co.uk/2021/11/22/delta-variant-could-mutate-its-way-out-of-existence-say-scientists-15645161/
VIDEO: Todos Medical on Benzinga
Gerald gives an outstanding interview. Lots of good info here on why Tollovir is superior to competitors. All we need now is the phase 2 trial results. Gerald sounds very confident in the trial outcome. This company is a rocket on the launchpad, fueled and ready, and the countdown to launch is in progress.
Video length: 9:54
Just pointing out the hypocrisy. After spending years trashing Gerald, don't start giving praise now. Doesn't seem sincere... more like trying to save face. Just my opinion and observation.
According to you, only novice or naive investors would invest with Gerald. However, this particular novice investor has done a lot of reading and research into Todos and Tollovir, and firmly believe Gerald has learned valuable lessons from his Amarantus failure which is helping him succeed with Todos.
Watch this novice investor make millions, all tax-free. Contrary to what you believe, I do actually know what I'm doing. I understand the risk and at this point of development, it was time to load up.
Wishing good fortune and Happy Thanksgiving to Todos Medical and Amarantus investors. We all have much to be thankful for. Wishing you a Happy Thanksgiving as well, JP.
As I predicted... now that the stock is moving higher and Todos with GC at the helm appears to be on the brink of major commercial success, the leopard is changing his spots.
What about these recent posts? I thought leopards don't change their spots (your words in reference to Gerald). Must be a different breed of leopard. The last one is my personal favorite. LOL Perhaps someone should contact Pfizer and warn them who they are dealing with.
Thanks for the well wishes. The 2M+ Todos shares in my Roth account thank you as well. I promise not to blame the CEO if I lose money. Mark these words. The responsibility for this risk is ALL MINE.
--------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------
Insider Financial: The 3CL Secret to Pfizer’s and Todos Medical’s Success
https://insiderfinancial.com/the-3cl-secret-to-pfizers-and-todos-medicals-success/182711/
I was part of that frenzy. Hit my target share goal with those purchases. Looking forward to news on trial data. Still have funds coming in later this week. Might try to pick up some AMBS shares to take advantage of their stake in Todos. GLTA
MONI back below 0.03. Even Thornton Melon didn't see this coming. He appears quite upset while waiting for "Girl Power" to do something about the steady share price decline over the last few months. You won't hear Thornton giving excuses like healthy consolidation or base support level being established to explain the decline. Thornton knows those are excuses shareholders dream up to keep from admitting they may have invested in what once appeared to be a floating turd, but is now a sinking turd.
Hard to say who is selling at this point. Flippers taking small profits, market makers shorting the stock, who knows? I don't believe it's our financiers dumping shares as some believe. GC has repeatedly stated they are not, plus now there's a lock-up agreement for these holders until mid-December. With their publicly-stated goal of helping the company uplist to Nasdaq, it doesn't make sense they would sell now when the company is approaching a major inflection point in share price with the pending release of Tollovir trial data.
Another thought... Gerald's recent video where he mentioned deaths in the trial patients may have spooked some investors who want to lower their exposure or risk. There is the possibility that one or more of the deaths occurred in the test group, even though that is 180 degrees out from what was observed in the 2020 observational study where deaths only occurred in the control group. That's the biggest risk at the moment and some may have decided it's too much risk for them.
But given what we know about the 5000 patients already dosed with Tollovir and having no reported side effects, and the decades of research by Dr. Dorit Arad at NLC Pharma on 3CL protease inhibitors, that possibility seems remote to me. I believe Gerald and others in the company feel the same, as their overall attitude toward the still unknown trial results tend to be extremely positive. They may not know the actual results yet, but they know what went into development of Tollovir and the outstanding results observed so far. Why would that change? All coronaviruses replicate via the same mechanism, and shutting down the 3CL Protease stops the virus in its tracks. This study was carefully planned and highly controlled to ensure the resulting data is solid. I believe they aren't just hoping for good results; they know instinctively the results are going to be great.
I'm good with the share price where it is at the moment, as I'm still buying shares ahead of the interim data report. Based on everything I've read of Dr. Arad's research, I think both Todos and Pfizer are on the right track to shut down this replication mechanism, but I believe Tollovir will prove to be the superior product because it is naturally derived and offers several benefits not observed in the Pfizer trial.
Good luck. Exciting weeks ahead.
Thanks. Great time to buy shares, which I am doing every day this week. Want to reach my target goal of Todos shares before the trial data is released.
Cool name, by the way. The Night Stalker was one of my favorite vampire movies as a kid. I remember the response it caused after being broadcast on ABC's Monday Night Movie. Scared the hell out of my sister. Lame by today's standards for a horror film, but damn scary at the time. Also watched The Night Stalker spinoff TV series.
Have the movie on DVD. One of my favorite Darren McGavin performances, the other being A Christmas Story.
Margins weren't disclosed in the press release. What we do know is this: Sales will be at wholesale price until manufacturing can be established in the region. Thereafter they will manufacture their own product and Todos will receive a double-digit royalty on each sale. We don't know if that's 10% or 90%, but if we make an assumption, just for analysis, that wholesale price is $50 per bottle and royalty is 50% for each sale at $100 per sale, that's $50 in revenue per bottle either way.
50,000 bottles x $50 = $2.5M for this initial order.
500,000 bottles x $50 = $25M minimum per the agreement over 18 months.
Real revenues could be higher or lower depending on wholesale price or royalty rate, but this is a middle-ground starting point for the minimum order per the agreement. If demand is for 5M bottles, revenue could be upwards of $250M.
Also, this is just for the Tollovid Daily product. They will evaluate demand for the full-strength Tollovid product which would bring significantly higher revenues. This could be a fantastic revenue stream depending on demand. Might be a bigger seller in Europe than in USA due to our politics whereby vaccines and boosters or big pharma drugs are promoted over more effective treatments such as Tollovid/Tollovir. Looking forward to interim trial data blowing a big hole in the current thinking.
Agreed. While some thought Todos was late to the party, with the way things are working out, it appears the others arrived early to drink beer out of the keg, while Todos is arriving later with the cases of champagne and the fine crystal in which to drink it... as though this was planned all along. One should note that GC has predicted much of what is unfolding up to a year ago in his Twitter posts.
No, clearly I missed that but it explains exactly what my question was about. Thanks for pointing it out.
NEWS: Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
https://investor.todosmedical.com/news-events/press-releases/detail/154/todos-medical-receives-purchase-order-for-50000-bottles-of
· T-Cell Protect is also evaluating expected demand for maximum strength Tollovid®
New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today announced it has received an initial purchase order from its European distribution partner T-Cell Protect Hellas S.A. (“T-Cell Protect” or “T-Cell”) for fifty thousand (50,000) bottles of its Tollovid Daily™ dietary supplement formulated product to be marketed under the T-Cell Protect brand (www.tcellprotect.com). The initial 50,000-bottle purchase order is expected to give T-Cell Protect a sufficient amount of product to complete its initial planned roll-out of T-Cell Protect to a subset of its 11,000 store retail distribution network throughout Greece, while also providing T-Cell Protect with sufficient marketing information to evaluate the relative number of maximum strength Tollovid® bottles it will need to purchase to fulfill demand for the Greek market for the first half of 2022. T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.
“We expect to see very strong demand in Greece and the rest of the European market for our new T-Cell Protect Products based on the Tollovid formulations as people are looking for additional layers of immune support heading into the winter,” said Themis Filippopoulos, President & CEO of T-Cell Protect. “Moving forward, we will be preparing a targeted campaign in a portion of our stores through the end of the year and into early 2022. Our initial focus is to conduct a targeted launch that aims to optimize marketing for the eight (8) largest countries in Europe before expanding throughout the continent. Our strategy is to go after the regions where the effects of the pandemic are most pronounced, where it overlaps with our strong retail footprint in Greece, and thereafter the rest of Europe. We believe that the Tollovid family of products marketed under the T-Cell Protect brand will be extremely well received in Europe where people are focused on more natural ways to support and maintain healthy immune function. The potential for Tollovid and Tollovid Daily in Europe is quite significant.”
“We are very excited to see our Tollovid family of products soon become available for purchase in Europe via a trusted partner with extensive experience in successfully bringing holistic products to market,” said Gerald Commissiong, President & CEO of Todos Medical. “We view this relationship with T-Cell Protect as very timely and lending significant credibility to our overall global marketing efforts for the ‘Tollo’ family of products. We intend to complete the evaluation and begin to move forward with similar agreements with trusted, local distribution partners in other markets in order to expand our geographic footprint across the globe in the months ahead. We believe this partnership with T-Cell Protect will have a significant impact in driving global adoption for the first family of dietary supplement products authorized by US Food & Drug Administration with 3CL protease inhibition claims.”
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Tollovid® & Tollovid Daily™
Tollovid and Tollovid Daily are dietary supplement products, made from natural ingredients, that help support and maintain healthy immune function, and are also 3CL protease inhibitor products based upon in vitro functional assays that show inhibition of 3CL protease activity. Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. Tollovid Daily is a twice daily immune support product that is designed to provide ongoing daily immune support for the person on the go.
About Tollovir®
Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.
About T-Cell Protect Hellas S.A.
T-Cell Protect Hellas (www.tcellprotect.com), based in Athens, Greece, is a European nutraceutical manufacturer and supplier of immune support dietary supplement products that is led by a world-class management team. The company has a retail distribution network of over 11,000 stores throughout Greece. Mr. Filippopoulos, the founder of the company, has been in the natural supplement industry for over 35 years and has launched some of the most well-known products in Europe with his vast retail network relationships. T-Cell Protect is rolling out the Tollovid family of products under the T-Cell brand throughout Europe.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
My prediction... no one will sell because interim trial data will have been announced, share price moves rapidly north, and investors realize at that point it's likely going much higher and not worth the risk of selling at the current price when the lockup expires..
Gerald did address this in his videos, where he describes the current funding investors having a long-term outlook with uplisting to Nasdaq as their goal. The funding sources currently in place are not like the last bunch, who have all now been replaced. The lockup agreement was mainly for investor confidence. GC doesn't need it to prevent selling from his current financiers, who are here for the long game.
Planning to substantially increase my TOMDF position over the next few days.
I agree, and I believe the success of Todos with Tollovir will help to resurrect Amarantus.
That's exactly the study I found before, just didn't save the link and had wiped my browser history since then so couldn't easily retrieve it. Good job finding it and translating for us.
For some reason this time the link wouldn't complete loading in my web browser, so I reconnected my VPN to Israel and it popped right up.
Can I ask how you translated? Did you use an online service or did you translate yourself? I tried Google Translator and it failed. I didn't spend much effort, however.
You make some good points regarding the trial, but with this being a double-blinded trial, neither the doctors, patients, nor the company knows which patient is receiving Tollovir or the placebo. That's done to eliminate bias in the study.
If there are deaths, there's no way to know which caused them... the drug being administered or not being administered.
My question is... are these patients receiving ANY other treatments for their condition or is it strictly Tollovir or placebo? If I was a patient being asked to participate in the trail, would that mean I would have a 50/50 chance of getting a drug that could save my life, or getting nothing and greatly increasing my chances of dying.
With that choice and realizing that no one knows what is being administered to me, I might elect to take my chances with the existing treatments, even though they are possibly far less effective. Many have still died getting the currently approved treatments. Plus, Todos is targeting patients already hospitalized with underlying medical conditions or significant symptoms, while their competitors are targeting pre-hospitalized patients. I suspect if our competitors were targeting the same trial group, they would also have trouble finding willing candidates.
Todos will likely have a much larger trial when they start a study of pre-hospitalized patients.
Here's an article that explains the basics of a double-blinded placebo-controlled study. I'm still learning about the specifics of these kinds of studies, and this is considered the "gold standard" of studies, as GC has stated. We have seen issues with some of our competitors trials that were rushed... failures, potential compromises making data questionable, and whistleblowers making claims of fraud. I believe Todos is taking the longer more difficult approach in order to ensure rock-solid trial data that will be upheld against all scrutiny and criticism.
https://www.verywellhealth.com/double-blind-placebo-controlled-clinical-trial-715861
And a more technical and detailed explanation from NIH.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505292/
I realize how it looks, but I zoomed in on the video and it appears this is not a piece of tape, but part of the random pattern of the background panel. There are no similar pieces of "tape" on the other corners of the sign, and the vertical pattern along the right edge of the sign is similar to the pattern of what appears to be tape.
I think this is just a coincidence and not a piece of tape, but I can certainly understand that interpretation. If the sign had been posted on the left side, this wouldn't even be an issue.
Looking forward to the data. If it mirrors the 2020 observational study, the deaths that occurred will be only in placebo patients, and while that is unfortunate for those patients, it will be a huge win for Tollovir and Todos investors, IMHO.
Possibly listed under NLC Pharma? Dr. Dorit Arad is heavily involved in the trial. Saw her on a recent interview but she was speaking in Hebrew so I had no idea what she was saying.
This story is definitely getting exciting. Loaded for bear here, and buying more this coming week before Thanksgiving. Could be a Very Merry Christmas for Todos shareholders will interim trial data being released in December, particularly if the deaths occurred in the placebo group as we suspect, based on the 2020 observational data where the only deaths occurred in the placebo group, and those in the dosed group all recovered, even though with severe conditions. Very likely the same outcome here, and we'll know soon.
I wouldn't expect the trial to be listed on the web site you mentioned since it is being conducted in Israel. I did find a site describing the trial, but it was in Hebrew and Google translator couldn't handle translating to English. If I can find the link again I will post it.
Gerald's Twitter posts today has a response to a question about the deaths that may shed more light on this aspect of the trial.
Share Structure Update - 11/19/21
No change in outstanding shares from last week.
https://www.otcmarkets.com/stock/TOMDF/security
Just another photo of Gerald for the collection. Infatuation at it's finest. Can't get over this man. I understand. Or perhaps I should have called him Gerlad, which is the pet name most often used.
Reasons?
1. Man Crush - most likely option given the extreme number of posts about the man
2. Anger - lost a lot of money investing with this man - next most likely option based on attacks posted
3. Gratitude - made a lot of money investing with this man - least likely option based on attacks posted
Perhaps we should take a poll of readers on these 3 options. My vote is for #1, since #2 is vigorously disputed and clearly #3 is listed only to round out the possibilities, but we know that's not really an option, don't we?
By the way, great news released this morning for Todos Medical, paving the way for outstanding interim trial results very soon. Onward and upward for TOMDF and AMBS.
NEWS: Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
https://investor.todosmedical.com/news-events/press-releases/detail/153/todos-medical-announces-completion-of-enrollment-for
• Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis
• Data from the interim analysis expected in the end of 4th Quarter of 2021
• Jules Mitchel, PhD, appointed as strategic advisor to assist with the interim analysis
New York, NY, and Tel Aviv, ISRAEL, Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today is very pleased announce an update regarding the ongoing clinical development of Tollovir®, a oral antiviral 3CL protease (3CLpro, Main protease, Mpro, Nsp5) inhibitor & anti-cytokine therapeutic candidate for the treatment of COVID-19. The enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel, Shaare Zedek Medical Center in Jerusalem and Hillel Yaffe Medical Center in Hadera, to allow for an interim analysis of the data. The Company expects data from the interim analysis to be reviewed by the trial Data Safety and Monitoring Board (DSMB) in the fourth quarter of 2021.
Concurrent with this announcement, the Company announced that it has retained the services of Jules Mitchel, PhD, to assist the Company with the interim analysis. Dr. Mitchel has an extensive background in the clinical trial and regulatory affairs space, previously serving as Founder & CEO of global clinical research organization (CRO) Target Health from its founding in 1993 until it was sold to dMed Biopharmaceuticals in 2019.
The interim analysis, previously scheduled to occur at 33 patients, will now be conducted on the 31 patients enrolled in the trial as of November 10, 2021 based on the recommendation from the statistician using blinded data that indicated the clinical trial has likely met the threshold required to evaluate futility.
The primary endpoints for the trial are:
1. Reduction in the duration of hospitalization
2. Time to clinical improvement as defined by the National Early Warning System 2 (NEWS2)
Secondary endpoints will include:
1. Death
2. Incidence and duration of time on supplemental oxygen
3. Incidence of deterioration and need for mechanical ventilation
In the event that a patient is intubated at the time of or after enrollment into the trial, Tollovir is able to be administered via feeding tube to continue therapy. Following the interim analysis, the Company will make decisions on the next steps in the clinical development program for Tollovir in COVID-19 for patients who are (1) hospitalized, (2) present with moderate disease, (3) have Long Haulers (Post –Acute Sequelae of SARS CoV-2) and (4) are less than 18 years of age.
“We are very happy with the acceleration of the clinical trial to the point that we will get our first controlled clinical data,” said Dr. Dorit Arad, Founder and Chief Scientific Officer of NLC Pharma. “We will now obtain the first placebo-controlled clinical trial data for Tollovir as an adjunct to the standard of care for the treatment of hospitalized COVID-19 patients, after promising data from our observational study conducted in 2020. We are very excited for this moment that could become a pivotal turning point for physicians who treat hospitalized COVID-19 patients.”
“Once Pfizer released its Phase 2/3 data on their drug candidate PAXLOVID™ in the outpatient setting, it clinically validated the 3CL protease as a stellar antiviral target that appears to be unaffected by variants,” said Gerald E Commissiong, President & CEO of Todos Medical. “The 3CL protease is a target capable of producing robust clinical outcomes. This gives us tremendous confidence going into this interim analysis that we should be able to confirm the strong efficacy signals seen in last year’s Tollovir observational study. We are confident that our naturally derived antiviral will have an enviable safety profile. If the interim results resemble the observational study, demonstrating a significant reduction of time in the hospital and death, it will cement the direction of our clinical trial pathway. We believe Tollovir could become a highly sought-after therapeutic candidate in the hospitalized setting which represents patients at the highest risk of death and the highest cost of care. The benefit of reducing time in the hospital would be quite significant, as it is expected to open up hospital capacity for non-COVID related ailments, which represents a significant benefit for patients and healthcare systems during COVID surges.”
DATA FROM 32 PATIENT OBSERVATIONAL STUDY CONDUCTED IN 2020
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Tollovir®
Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.
Dude, there are thousands of posts I've read through on this board. To date, 5,113 of them are by you. Not to mention SEC filings and press releases. I would say I have a very good understanding of what transpired back then. But the message board gives the biggest clue as to who got in over their head and who didn't.
We're not talking about a leopard, but a man. History is filled with men and women who failed miserably, learned from their failures, and succeeded later on. I believe that's what we're witnessing with Todos, and ultimately a rebirth of Amarantus.
You may have been hammered in your investment, but that doesn't mean you know anything more about this venture than you did the last one. The only thing YOU know are the reasons YOU won't invest with GC again. Understood. Message received. But you're wasting your time trying to convince others because they understand what I stated above about failure and will made decisions based on what is happening NOW, not back then. History is a reminder and a guide, not the road map for the future.